Patents Assigned to Bristol-Myers Company
-
Patent number: 5218106Abstract: There are disclosed novel 2',3'-dideoxy-2'-fluoronucleosides and 2'-3'-dideoxy-2',3'-didehydro-2'-fluoronucleosides and processes for their preparation. The compounds so produced exhibit therapeutically useful antiviral and, more particularly, anti-HIV effects.Type: GrantFiled: March 26, 1992Date of Patent: June 8, 1993Assignee: Bristol-Myers CompanyInventors: Roman Z. Sterzycki, Muzammil M. Mansuri, John C. Martin
-
Patent number: 5164379Abstract: Complexes of sucralfate with alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin or 2-hydroxypropyl beta cyclodextrin are disclosed. Also disclosed are a process for producing complexes and compositions and a method for reducing gastric injury, employing the complexes.Type: GrantFiled: July 15, 1991Date of Patent: November 17, 1992Assignee: Bristol-Myers CompanyInventors: Randy J. Koslo, Vincent J. Farina
-
Patent number: 5130421Abstract: There are disclosed novel processes for producing 2',3'-dideoxy-2'3'-didehydronucleosides, for example, 2',3'-dideoxy-2',3'-didehydrothymidine in high yields and on a large scale. The compounds so-produced are useful as antiviral agents, especially as agents effective against the human immunodeficiency viruses (HIV).Type: GrantFiled: April 29, 1991Date of Patent: July 14, 1992Assignee: Bristol-Myers CompanyInventors: John E. Starrett, Jr., Muzammil M. Mansuri, John C. Martin, Carl E. Fuller, Henry G. Howell
-
Patent number: 5126506Abstract: There are disclosed novel 2',3'-dideoxy-2'-fluoronucleosides and 2'-3'-dideoxy-2',3'-didehydro-2'-fluoronucleosides and processes for their preparation. The compounds so produced exhibit therapeutically useful antiviral and, more particularly, anti-HIV effects.Type: GrantFiled: September 13, 1990Date of Patent: June 30, 1992Assignee: Bristol-Myers CompanyInventors: Roman Z. Sterzycki, Muzammil M. Mansuri, John C. Martin
-
Patent number: 5120862Abstract: There is provided a novel and efficient stereoselective total synthesis of epipodophyllotoxin and related epipodophyllotoxin compounds of the and present invention ##STR1## wherein R.sup.1 and R.sup.2 each are independently hydrogen or (lower)alkoxy, or R.sup.1 ll and R.sup.2, taken together, is methylenedioxy; R.sup.4 and R.sup.6 each are independently hydrogen or (lower)alkoxy; and R.sup.5 is hydrogen or a phenol-protecting group; or an acid addition salt thereof. The present ivnention also provides novel intermediates and processes for the preparation of said intermediates, which are then converted into known antineoplastic agents.Type: GrantFiled: October 4, 1991Date of Patent: June 9, 1992Assignee: Bristol-Myers CompanyInventors: Dolatrai M. Vyas, Paul M. Skonezny
-
Patent number: 5116845Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.Type: GrantFiled: May 4, 1990Date of Patent: May 26, 1992Assignee: Bristol-Myers CompanyInventors: Hiroaki Ohkuma, Masataka Konishi, Kiyoshi Matsumoto, Toshikazu Oki, Yutaka Hoshino
-
Patent number: 5114857Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.Type: GrantFiled: May 14, 1991Date of Patent: May 19, 1992Assignee: Bristol-Myers CompanyInventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
-
Patent number: 5110940Abstract: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or trifluoromethyl;R.sup.2,R.sub.3,R.sup.5 and R.sup.6 each are independently hydrogen, halogen C.sub.1-4 alkyl or C.sub.1-4 alkoxy;tet is ##STR2## n is an integer of from 0 to 2, inclusive; A is ##STR3## R.sup.7 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy(lower) alkyl or (2-methoxyethoxy)methyl;X is --OH or .dbd.O; andR.sup.8 is hydrogen, a hydrolyzable ester group or a cation to form a non-toxic pharmaceutically acceptable salt,are novel antihypercholesterolemic agents which inhibit cholesterol biosynthesis. Intermediates and processes for their preparation are disclosed.Type: GrantFiled: May 6, 1991Date of Patent: May 5, 1992Assignee: Bristol-Myers CompanyInventors: Sing-Yuen Sit, John J. Wright
-
Patent number: 5110960Abstract: Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.Type: GrantFiled: October 1, 1990Date of Patent: May 5, 1992Assignee: Bristol-Myers CompanyInventors: Toshikazu Oki, Kyoichiro Saitoh, Kozo Tomatsu, Koji Tomita, Masataka Konishi, Takeo Miyaki, Mitsuaki Tsunakawa, Maki Nishio
-
Patent number: 5106996Abstract: There are disclosed intermediates which can be converted into podophyllotoxin and related compounds, which are known antineoplastic agents. There are also disclosed processes for the preparation of such intermediates, and processes for the conversion of the intermediates into known intermediates which are readily converted into podophyllotoxin and related compounds.Type: GrantFiled: July 25, 1990Date of Patent: April 21, 1992Assignee: Bristol-Myers CompanyInventors: Takushi Kaneko, Henry S. L. Wong
-
Patent number: 5099016Abstract: The present invention provides novel mitomycin analogs containing a disulfide group and processes for the preparation thereof. These compounds are mitomycin A analogs in which the 7-alkoxy group bears an organic substituent incorporating a disulfide group. Mitomycin A is an antibiotic of established utility, and the 7-O-substituted mitosane analogs thereof have similar utility.Type: GrantFiled: February 26, 1990Date of Patent: March 24, 1992Assignee: Bristol-Myers CompanyInventors: Dolatrai M. Vyas, Terrence W. Doyle, Richard A. Partyka
-
Patent number: 5096817Abstract: Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.Type: GrantFiled: December 14, 1990Date of Patent: March 17, 1992Assignee: Bristol-Myers CompanyInventors: Maki Nishio, Yosuke Sawada, Takeo Miyaki, Toshikazu Oki
-
Patent number: 5097036Abstract: The present invention provides novel mitomycin analogs containing a disulfide group and processes for the preparation thereof. These compounds are mitomycin A analogs in which the 7-alkoxy group bears an organic substituent incorporating a disulfide group. Mitomycin A is an antibiotic of established utility, and the 7-O-substituted mitosane analogs thereof have similar utility.Type: GrantFiled: February 26, 1990Date of Patent: March 17, 1992Assignee: Bristol-Myers CompanyInventors: Dolatrai M. Vyas, Terrence W. Doyle, Richard A. Partyka
-
Patent number: 5095011Abstract: A stable, amorphous, lyophilized dihydrochloride salt of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinium) methyl]-3-cephem-4-carboxylate is described. This lyophilized salt is more easily prepared than the crystalline counterpart and can be reconstituted in effective concentrations for intramuscular and intravenous injection utilizing suitable organic and inorganic bases to pH 3-7.0.Type: GrantFiled: December 20, 1990Date of Patent: March 10, 1992Assignee: Bristol-Myers CompanyInventors: Murray A. Kaplan, Munir N. Nassar
-
Patent number: 5089526Abstract: A process is provided for preventing or ameliorating arrhythmia by administering to mammals, including man, an effective dose of d-sotalol to lengthen the action potential duration of cardiac cell without blockade of beta-adrenergic receptor sites.Type: GrantFiled: December 23, 1986Date of Patent: February 18, 1992Assignee: Bristol-Myers CompanyInventors: Arthur Simon, Jeff A. Thomis
-
Patent number: 5086182Abstract: There is provided a novel and efficient stereoselective total synthesis of epiodophyllotoxin and related epipodophyllotoxin compounds of the general formula ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen or (lower)-alkoxy, or R.sup.1 and R.sup.2, taken together, is methylenedioxy; R.sup.4 and R.sup.6 each are independently hydrogen or (lower) alkoxy; and R.sup.5 is hydrogen or a phenol-protecting group; or an acid addition salt thereof. The present invention also provides novel intermediates and processes for the preparation of said intermediates, which are then converted into known antineoplastic agents.Type: GrantFiled: February 13, 1991Date of Patent: February 4, 1992Assignee: Bristol-Myers CompanyInventors: Dolatrai M. Vyas, Paul M. Skonezny
-
Patent number: 5073633Abstract: An antitumor antibiotic designated BMY-41950 is produced by fermentation of Streptomyces staurosporeus ATCC 55006 or Streptomyces hygroscopicus ATCC 53730. The BMY-41950 antibiotic exhibits both antimicrobial and antitumor activities.Type: GrantFiled: November 5, 1990Date of Patent: December 17, 1991Assignee: Bristol-Myers CompanyInventors: Daniel Schroeder, Kin S. Lam, Jacqueline Mattei, Grace A. Hesler
-
Patent number: 5071957Abstract: The antibiotic designated BU-4061T is produced by fermentation of actinomycete strain Q996-17 (ATCC-53904). The BU-4061T antibiotic exhibits both in vitro and in vivo antitumor activity.Type: GrantFiled: October 4, 1990Date of Patent: December 10, 1991Assignee: Bristol-Myers CompanyInventors: Masataka Konishi, Minoru Hanada, Yuji Nishiyama
-
Patent number: 5070206Abstract: Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or trifluoromethyl;R is hydrogen, C.sub.1-4 alkyl or phenyl;A is ##STR2## R.sup.5 is hydrogen, a hydrolyzable ester group or a cation to form a non-toxic pharmaceutically acceptable salt,are novel antihypercholesterolemic agents which inhibit cholesterol biosynthesis. Intermediates and processes for their preparation are disclosed.Type: GrantFiled: February 13, 1991Date of Patent: December 3, 1991Assignee: Bristol-Myers CompanyInventors: Sing-Yuen Sit, John J. Wright
-
Patent number: 5068346Abstract: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or trifluoromethyl;R.sup.2, R.sup.3,R.sup.5 and R.sup.6 each are independently hydrogen, halogen C.sub.1-4 alkyl or C.sub.1-4 alkoxy;tet is ##STR2## n is an integer of from 0 to 2, inclusive; A is ##STR3## R.sup.7 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy(lower) alkyl or (2-methoxyethoxy)methyl;X is --OH or .dbd.O; andR.sup.8 is hydrogen, a hydrolyzable ester group or a cation to form a non-toxic pharmaceutically acceptable salt,are novel antihypercholesterolemic agents which inhibit cholesterol biosynthesis. Intermediates and processes for their preparation are disclosed.Type: GrantFiled: November 17, 1989Date of Patent: November 26, 1991Assignee: Bristol-Myers CompanyInventors: Sing-Yuen Sit, John J. Wright